5 completed. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
Follow Dendreon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer sipuleucel-T - Adenocarcinoma of the Prostate | Phase 3 | Completed | Dendreon | 532 | 2018-10-18 | 2024-10-08 |
| Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Sipuleucel-T, APC-Placebo - Prostate Cancer | Phase 3 | Completed | Dendreon | 512 | 2003-07-01 | 2010-09-06 |
| PROvenge Treatment and Early Cancer Treatment Control, Sipuleucel-T - Prostate Cancer | Phase 3 | Completed | Dendreon | 176 | 2001-10-01 | 2018-01-29 |
| Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer sipuleucel-T, APC-Placebo - Hormone-Refractory Prostate Cancer | Phase 3 | Completed | Dendreon | 98 | 2000-05-01 | 2010-09-08 |
| Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy sipuleucel-T, Placebo - Prostate Cancer | Phase 3 | Completed | Dendreon | 127 | 1999-11-01 | 2010-11-01 |
Prostatic Neoplasms (3) · Neoplasms (1)
sipuleucel-T (5)
United States (4) · Canada (1)
Eric J. Small, MD (1) · Nadeem Sheikh, PhD (1) · Paul Schellhammer, MD (1) · Robert Israel, MD (1)
PMID 24957547, PMID 35812443, PMID 16809734, PMID 20818862, PMID 23253957, PMID 23896100